Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 27, 1997. Haemonetics Corporation is a global manufacturer of medical equipment and disposables for blood management, including blood collection, processing, and transfusion. The company operates significant international sales channels and has recently expanded its Blood Bank Management Services (BBMS) division through acquisitions.
Key Financial Metrics
| Metric | Three Months Ended Sep 27, 1997 | Six Months Ended Sep 27, 1997 |
|---|---|---|
| Net Revenues | $76.6 million | $158.9 million |
| Gross Profit | $34.5 million (45.1% margin) | $71.6 million (45.0% margin) |
| Operating Income | $6.1 million (8.0% margin) | $15.7 million (9.9% margin) |
| Net Income | $4.0 million ($0.15/share) | $10.5 million ($0.39/share) |
| Cash and Equivalents | $6.6 million (Balance Sheet) | N/A |
| Working Capital | $116.1 million | N/A |
| Long-Term Debt | $49.9 million (net of current) | N/A |
| Operating Cash Flow | N/A | ($5.0 million) used |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 3% year-over-year for the quarter and 6% for the six-month period. Excluding currency effects, growth was 7% and 12% respectively, driven by a 5% increase in worldwide disposable sales.
- Margin Compression: Gross profit margins declined significantly from 53.6% to 45.1% (quarterly) and 54.8% to 45.0% (six-month). This was attributed to a stronger U.S. dollar, higher manufacturing costs, product mix shifts, and investments in BBMS.
- Profitability Decline: Operating income dropped from $12.9 million to $6.1 million for the quarter, and net income fell from $8.6 million to $4.0 million. Operating margins contracted from 17.3% to 8.0%.
- Cash Flow Reversal: Operating cash flow turned negative, using $5.0 million in the first six months of 1997 compared to generating $13.6 million in the prior year. This was due to increased inventory levels and accounts receivable.
- Debt Increase: Long-term debt increased substantially to fund acquisitions and working capital, with interest expense rising 84% year-over-year for the quarter.
Outlook, Risks, and Management Commentary
- Capital Raising: On October 28, 1997, the company completed a private placement of $40.0 million in unsecured senior notes with a 7.05% coupon rate and a ten-year term to support liquidity.
- Acquisitions: The company acquired three blood centers for approximately $10.5 million in cash during the period, adding $4.9 million in goodwill. These acquisitions are driving SG&A expense increases.
- Foreign Exchange: The strengthening of the U.S. dollar negatively impacted reported revenues and margins. The company holds $96.3 million in forward exchange contracts to hedge future sales commitments.
- Share Repurchases: The company repurchased 318,700 shares of treasury stock for $5.6 million during the six-month period. Approximately 271,000 shares remain available for repurchase.
- Risks: Key risks include continued currency volatility, the ability to integrate BBMS acquisitions profitably, and the need to manage working capital growth alongside capital expenditures.
Investor Verification Checklist
- Verify the sustainability of the 45% gross margin given the mix shift to lower-margin plasma disposables and BBMS service revenue.
- Confirm the impact of the new $40 million senior notes on future interest expense and debt covenants.
- Monitor the integration progress and profitability timeline of the three acquired blood centers.
- Assess the adequacy of working capital given the negative operating cash flow and rising inventory levels.
- Review the effectiveness of foreign currency hedging strategies against the strengthening dollar.